Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|
Vaidya, n., karmacharya, r.M., vaidya, s., bade, s., bade, s., poudel, k., kandel, g., thapa, p.Massive hemoptysis and pulmonary t hromboembolism in a patient with pulmonary tuberculosis: a therapeutic conundrum managed with bronchial artery embolization.Kathmandu univ med j.20; 4:80 summary: hemoptysis is a crucial entity taking into account its morbidity and mortality.Pulmonary tuberculosis is the leading cause for massive hemoptysis in our part of the world, which if left untreated may be life threatening.We present a case of a 37-year-old male patient with pulmonary tuberculosis with concurrent pulmonary thromboembolism presenting with massive hemoptysis, which was successfully managed with bronchial artery embolization.This case represents that this measure can be a viable therapeutic choice for a patient with a severe lifethreatening hemoptysis, particularly when other treatment options are unavailable or ineffective.Reported events: a 51-year-old patient developed severe pain in posterior part of left chest probably due to ischemia following embolization of dorsal scapular artery.The pain subsided in about 30 minutes following intravenous analgesics.The patient was admitted for two days and was discharged with oral anticoagulant agents to prevent further embolic episodes along with anti-tubercular therapy.Following the procedure, the patient hasn¿t complained of hemoptysis till the current follow-up of two months.
|